US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

3.59

0.0000

Volume:149

Turnover:532.58

Market Cap:42.21M

PE:-3.36

High:3.59

Open:3.59

Low:3.59

Close:3.59

52wk High:9.50

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:0.09

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:3.84

PE(LYR):-4.91

Loading ...

Overview Company News Filings

Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial

Nasus Pharma - Pivotal Study Planned for Q4 2026; Topline Data Readout Anticipated Q1 2027

THOMSON REUTERS

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of Ns002 in the Treatment of Anaphylaxis

THOMSON REUTERS

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Amex Halt Add Info Lst 3.470000

THOMSON REUTERS

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool

Nasus Pharma Announces Annual, Special Shareholder Meeting

Nasus Pharma Files $50 Million Shelf Registration

MT Newswires Live

Nasus Pharma files $50M ordinary shares offering

Nasus Pharma - May Offer up to $50 Mln of Ordinary Shares - SEC Filing

THOMSON REUTERS

Amex Halt Add Info Lst 3.500000

THOMSON REUTERS

Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns

Nasus Pharma CFO Eyal Rubin to Exit; Finance Director Oren Elmaliach Named Interim CFO

Nasus Pharma - Oren Elmaliach Appointed Interim Chief Financial Officer at Nasus Pharma

THOMSON REUTERS

Press Release: Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Benzinga Earnings

Nasus Pharma H1 FY26 Net Loss Widens to $5.94 Million

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/NSRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.59,"timestamp":1789567350490,"preClose":3.59,"halted":0,"volume":149,"delay":0,"changeRate":0,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Trading","change":0,"latestTime":"09-16 10:25:33 EDT","open":3.59,"high":3.59,"low":3.59,"amount":532.576809,"amplitude":0,"askPrice":3.79,"askSize":15,"bidPrice":3.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.06915,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.59,"postHourTrading":{"tag":"盘后","latestPrice":3.59,"preClose":3.59,"latestTime":"19:30 EDT","volume":9,"amount":32.03,"timestamp":1789515005622,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.087964},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":0.087964,"shares":11758900,"dividePrice":0,"high":3.59,"amplitude":0,"preClose":3.59,"low":3.59,"week52Low":1.98,"pbRate":"3.84","week52High":9.5,"institutionHeld":0,"latestPrice":3.59,"committee":0.73913,"eps":-1.06915,"divideRate":0,"volume":149,"delay":0,"ttmEps":-1.06915,"open":3.59,"prevYearClose":9.15,"prevWeekClose":3.4049,"prevMonthClose":4.084,"prevQuarterClose":3.5,"fiveDayClose":3.55,"twentyDayClose":3.65,"sixtyDayClose":3.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-09-15","current":-3.357808,"percent":0.98524,"low":-51.389177,"twenty":-44.647674,"median":-28.042344,"eighty":-5.859404,"high":-3.720961,"avg":-24.472731,"sd":17.690315,"marketCap":42755399},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610},{"date":"2026-08-28","current":-4.552846,"twenty":-44.798471,"median":-29.220042,"eighty":-6.059383,"marketCap":48014312},{"date":"2026-09-04","current":-4.164188,"twenty":-44.647674,"median":-28.450561,"eighty":-6.019387,"marketCap":43915530},{"date":"2026-09-11","current":-3.720961,"twenty":-44.647674,"median":-28.266216,"eighty":-5.923397,"marketCap":39241256},{"date":"2026-09-15","current":-4.054182,"twenty":-44.647674,"median":-28.042344,"eighty":-5.859404,"marketCap":42755399}],"updateTime":1789568733974},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667698696","title":"Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667698696","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667698696?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:47","pubTimestamp":1789390067,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has shared an announcement. On September 14, 2026, Nasus Pharma announced that the U.S. Food and Drug Administration ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665937","title":"Nasus Pharma - Pivotal Study Planned for Q4 2026; Topline Data Readout Anticipated Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665937?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA9BKDGC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667663014","title":"Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of Ns002 in the Treatment of Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667663014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667663014?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA9BKDGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665532","title":"Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665532","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665532?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen for patients experiencing anaphylaxis and will compare self-admini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361032/0/en/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-ns002-in-the-treatment-of-anaphylaxis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4007","NSRX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539006","title":"Amex Halt Add Info Lst 3.470000","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539006","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539006?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:11","pubTimestamp":1788966660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nAQN2MIKGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665781403","title":"Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665781403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665781403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867000,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Sept.  08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\"Nasus\", “Nasus Pharma” or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357529/0/en/nasus-pharma-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665351615","title":"Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool","url":"https://stock-news.laohu8.com/highlight/detail?id=2665351615","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665351615?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:28","pubTimestamp":1788553680,"startTime":"0","endTime":"0","summary":"The latest update is out from Nasus Pharma Ltd. ( ($NSRX) ). Nasus Pharma Ltd. has called an Annual and Special General Meeting of shareholders for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-october-8-2026-shareholder-meeting-to-vote-on-governance-executive-pay-and-option-pool?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-sets-october-8-2026-shareholder-meeting-to-vote-on-governance-executive-pay-and-option-pool?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359233","title":"Nasus Pharma Announces Annual, Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359233","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359233?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:06","pubTimestamp":1788552384,"startTime":"0","endTime":"0","summary":"Nasus Pharma announces annual, special shareholder meetingNasus Pharma will hold its annual and special general meeting of shareholders in Tel Aviv, Israel on Oct. 8, 2026.Votes will cover reappointin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL6BzZj4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664275861","title":"Nasus Pharma Files $50 Million Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2664275861","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664275861?lang=en_us&edition=fundamental","pubTime":"2026-09-02 05:56","pubTimestamp":1788299811,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) on Tuesday filed a prospectus to offer up to $50 million of ordinary shares from time to time in one or more offerings, with pricing and terms to be set in future supplements.The company plans to use the net proceeds for working capital and general corporate purposes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664861386","title":"Nasus Pharma files $50M ordinary shares offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2664861386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664861386?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:55","pubTimestamp":1788296108,"startTime":"0","endTime":"0","summary":"16:52 EDT Nasus Pharma (NSRX) files $50M ordinary shares offering Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-files-50m-ordinary-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-files-50m-ordinary-shares-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886909","title":"Nasus Pharma - May Offer up to $50 Mln of Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886909?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:51","pubTimestamp":1788295912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664868515","title":"Amex Halt Add Info Lst 3.500000","url":"https://stock-news.laohu8.com/highlight/detail?id=2664868515","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664868515?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:15","pubTimestamp":1788279309,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nAQN2MHJNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426740","title":"Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426740","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426740?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:47","pubTimestamp":1787147264,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has provided an update. Nasus Pharma Ltd. reported on August 19, 2026, that Chief Financial Officer Eyal Rubin has re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-names-interim-cfo-as-longtime-finance-chief-resigns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447838","title":"Nasus Pharma CFO Eyal Rubin to Exit; Finance Director Oren Elmaliach Named Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447838","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660447838?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137251,"startTime":"0","endTime":"0","summary":"Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFONasus Pharma CFO Eyal Rubin will leave to pursue an opportunity outside the life sciences industry.Rubin will rema","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL9JvcQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BQXX3F31.USD","BK4588","BK4007","BK4112","BCDF","IE00B64PRP62.GBP","NSRX","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","IE00BQXX3D17.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660027442","title":"Nasus Pharma - Oren Elmaliach Appointed Interim Chief Financial Officer at Nasus Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2660027442","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660027442?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA4PKWBX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660004442","title":"Press Release: Nasus Pharma Announces Transition of Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660004442","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660004442?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:00","pubTimestamp":1787137200,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) (\"Nasus\", \"Nasus Pharma\" or the \"Company\"), a clinical-stage pharmaceutical company focused on the developme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660389954","title":"Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660389954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660389954?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:22","pubTimestamp":1786972943,"startTime":"0","endTime":"0","summary":"An update from Nasus Pharma Ltd. ( ($NSRX) ) is now available. Nasus Pharma filed a Form 6-K in August 2026, providing unaudited condensed consolid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-boosts-cash-and-equity-in-first-half-2026-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-boosts-cash-and-equity-in-first-half-2026-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4215","BK4585","BK4588","REZ","VMRK","BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660875094","title":"Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660875094","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660875094?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:15","pubTimestamp":1786968947,"startTime":"0","endTime":"0","summary":"Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61243652/nasus-pharma-h1-eps-0-54-misses-0-20-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487516","title":"Nasus Pharma H1 FY26 Net Loss Widens to $5.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487516?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:14","pubTimestamp":1786968889,"startTime":"0","endTime":"0","summary":"Nasus Pharma H1 FY26 net loss widens to $5.94 millionNasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million.R&D expense rose to USD 2.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8nPTMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4585","BK4007","BCDF","SG9999014005.SGD","SG9999014013.SGD","NSRX","LU0314104364.USD","BK4112","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4588","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2095319765.USD","NDAQ","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848759","title":"Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848759?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:14","pubTimestamp":1786968869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA3XWYVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}